FDA Updates Sunscreen Safety Guidelines, Strengthening OTC Suncare Regulations for Kenvue, L'Oréal, and Others
Update of FDA Over-the-Counter (OTC) Sunscreen Guidelines and Public Health Context
The Center for Drug Evaluation and Research (CDER) under the U.S. Food and Drug Administration (FDA) has released updated public health guidelines detailing proper sunscreen usage and instructions for preventing photodamage. In the United States, sunscreen is strictly regulated under the Over-the-Counter (OTC) monograph system as a drug rather than a cosmetic, and daily use of broad-spectrum products that block both ultraviolet A (UVA) and ultraviolet B (UVB) rays with a Sun Protection Factor (SPF) of 15 or higher is recommended. This measure is interpreted as a proactive intervention by regulatory authorities aimed at reducing the incidence of non-melanoma skin cancer (NMSC) and melanoma, which occur in millions of cases annually, and preventing photoaging.
GRASE Certification Status and Regulatory Barriers for Active Ingredients
Under current U.S. federal regulations, only two active ingredients are generally recognized as safe and effective (GRASE): the inorganic mineral filters zinc oxide and titanium dioxide. On the other hand, 12 widely used organic chemical filters, including avobenzone, oxybenzone, and homosalate, are still in a conditional exemption status, requiring submission of clinical data from systemic absorption assessments (MUsT, Maximal Usage Trial). The threshold for FDA safety evidence requirements has significantly increased following the Over-the-Counter Monograph Reform (OMOR) under the Coronavirus Aid, Relief, and Economic Security (CARES) Act enacted in 2020.
$12 Billion Global Suncare Market Landscape and Commercialization Competition Among Major Companies
The global sunscreen market was valued at approximately $12.44 billion in 2024 and is projected to reach $15.92 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.2%. Competition is concentrated among Kenvue (KVUE), which owns the Neutrogena and Aveeno brands; L'Oréal (OR.PA), featuring Anthelios and CeraVe; Edgewell Personal Care (EPC), manufacturer of Banana Boat; and Beiersdorf (BEI.DE), which owns Coppertone. The strengthening of safety guidelines is serving as a catalyst to accelerate the market share expansion of premium dermacosmetic brands.
Portfolio Restructuring Centered on Inorganic Mineral Sunscreen Agents and Future R&D Directions
Driven by regulatory pressure and the reef-safe trend, the development of inorganic mineral sunscreen formulations, which are experiencing high growth of over 13% annually, has emerged as a key priority for the industry. Major pharmaceutical and beauty companies are concentrating investment in formulation technology to secure nano and non-nano Zinc Oxide-based formulas that improve white cast and application texture. Depending on whether the FDA's Final Administrative Order is finalized, companies may face costs associated with the phase-out of organic filters or the supplementation of clinical data, making proactive pipeline management essential.
In the short term, compliance with strict FDA guidelines and broad-spectrum labeling certification is expected to further raise entry barriers for major brands such as Kenvue (KVUE) and L'Oréal (OR.PA). In the medium to long term, the value of inorganic mineral pipelines based on Zinc Oxide and Titanium Dioxide, which have firmly established their marketed status in the $12.4 billion global sunscreen market, will rise sharply. Conversely, competitors such as Edgewell (EPC), which rely heavily on organic ingredients like avobenzone, may face the risk of regulatory reclassification and additional clinical expenditures amounting to millions of dollars to demonstrate systemic absorption safety. Consequently, the strengthened OTC monograph regulatory environment is expected to bring structural benefits to global healthcare oligopolistic firms equipped with their own formulation clinical research capabilities and capital.
Source: FDA Drug Approvals (rss)